請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51207
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 潘子明 | |
dc.contributor.author | Kai-Chun Hu | en |
dc.contributor.author | 胡凱鈞 | zh_TW |
dc.date.accessioned | 2021-06-15T13:27:30Z | - |
dc.date.available | 2016-03-08 | |
dc.date.copyright | 2016-03-08 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-02-15 | |
dc.identifier.citation | 王舒徽。2000。原生菌之機能性簡介。食品工業。32: 41-51。
邱雪惠。2004。乳酸菌之抗癌機制。食品工業。36(3): 27-33。 行政院衛生福利部。2010。健康食品之胃腸功能改善評估方法。行政院衛生福利部公告署食字第 0920401629 號。行政院衛生福利部。台北。台灣。 黃美瑩。2006。乳酸菌之保健功效。水試專訓。14: 43-45。 Akalin AS, Gonc S, Akbas Y. 2002. Variation in organic acids content during ripening of pickled white cheese. J Dairy Sci. 85: 1670-1676. Arunachalam KD. 1999. Role of bifidobacteria in nutrition, medicine and technology Nutr Res 19: 1559-1597. Ballongue J. 1997. Technical problems related to in vitro study of colon flora. Scand J. Gastroenterol. 32 Suppl. 222: 14-16. Bengmark S. 2000. Bacteria for optimal health. Nutr. 16: 611-615. Bouhnik Y, Flourie BD Agay-Abensour L, Pochart P, Gramet G, Durand M and Rambaud JC. 1997. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J of Nutr. 127: 444-448. Chang JH, Shim YY, Cha SK & Chee KM. 2010. Probiotic characteristics of lactic acid bacteria isolated from kimchi. J of Appl. Microbio. 109: 220–230. Cotter C, & Hill RP. 2004. Ross, bacterial lantibiotics: Strategies to improve therapeutic potential, Curr Prot Pept Sci. 6: 61–75. Cummings JH and Macfarlane GT. 1991. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol. 70: 443-459. Don J, Noel R, James T. 2005. The Gammaproteobacteria. Bergey's Manual of Systematic Bacteriology (2nd ed.): 1108. FDA. 1992. Clostridium perfringens. In “Bacteriological Analytical Manual”. 7th edition, Chap. 16: 209-214. Fuller R 1989. Probiotics in man and animals. J Appl Bacteriol. 66: 365-478. Gibson GR, Roberfroid MB. 1995. Dietary modulation of human colonic microbiota: Introduccing the concept of prebiotics. J Nutr. 125: 1401-1412. Gibson GR, Wang X. 1994. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 77: 412-420. Granum PE. 1990. Clostridum perfringenes toxins involved in food poisoning. Int J Food Microbiol 10: 101-112. Grill-Spector K, Kourtzi Z, & Kanwisher N. 2001. The lateral occipital complex and its role in object recognition. Vision Research. 41: 1409-1422. Guerin-Danan C, Andrieux C, Popot F, Charpilienne A, Vaissade P, Gaudichon C, Pedone C, Bouley C, and Szylit O. 1997. Pattern of metabolism and composition of the fecal microflora in infants 10 to 18 months old from day care centers. J Peditatr Gastroenterol Nutr. 25: 281-289. Hancock RD, Viola R. 2001. The use of micro-organisms for L-ascorbic acid production: current status and future perspectives. Appl Microbio and Biotech. 56: 567-576. Hawrelak JA, Myers SP. 2004. The causes of intestinal dysbiosis: A review. Altern Med Rev 9: 180-197. Hirayama K, & Rafter J. 2000. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2: 681-686. Hitchins AD, McDonough FE. 1989. Prophylactic and therapeutic aspects of fermented milk. Am J Clin Nutr. 49: 675-684. Holmes E, Li JV, Athanasiou TH and Nicholson JK. 2001. Understanding the role of gut mocrobiome-host metabolic signal disruption in health and disease. Trends Microbiol. 19: 349-359. Holzapfel WH, Haberer P, Snel J, Schillinger U. 1998. Overview of gut flora and probiotics. Int J Food Microbiol 41: 85-101. Hoover D. 1993. Bifidobacteria: avtivity and potential benefits. Food Tech. 47: 120-125. Hughes R, Rowland IR. 2000. Metabolic activities of the gut microflora in relation to cancer. Microb Ecol Health Dis Suppl 2: 179-185. Khedkar CD, Garge RD, Mantri JM, Kulkarni SA, & Khedkar GD. 1993. Effect of feeding acidophilus milk on serum cholesterol in human volunteers. J. Dairying, Foods & Home Sci. 12: 33-38. Kim D, Kang J, Park S, and Kobashi K. 1994. Characterization of β-glucosidase and β-glucuronidase of alkalotolerant intestinal bacteria. Biol Pharm Bull. 17: 423-426. Kim JG, Lee E, Kim SH, Whang KY, Oh S, & Imm JY. 2010. Effects of a Lactobacillus casei 393 fermented milk product on bone metabolism in ovariectomised rats. Intern Dairy J. 19: 690-695. Klaver FAM, & van der Meer R 1993. The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol. 59: 1120-1124. Kopp-Hoolihan L. 2001. Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc. 101: 229-238. Lin M. 1995. The beneficial effects of lactic acid bacteria on human health. J Chinese Nutr Soci. 20: 367-380. Ling WH. 1995. Diet and colonic microflora interaction in colorectal cancer. Nutr Res 15: 439-454. Liu H, Kristin D, Howarth D, JonathonH, David N, Popham L, Jensen R, Roderick V, Melville B, Stephen B. 2014. Hypermotility in Clostridium perfringens strain SM101 is due to spontaneous mutations in genes linked to cell division. J Bact. 196: 2405–2412. Mitsuoka T. 1996. Intestinal flora and human health. Asia Pacific J Clin Nutr 5: 2-9. Mutai M, Tanaka R. 1987. Ecology of Bifidobacterium in human intestinal flora. Bifidobacteria Microflora 6: 33-41. Naidu AS, Bidlack WR, Clemens RA. 1999. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 39: 113-126. Ohirchuk KS, Poltavs'ka OA, Kovalenko NK. 2013. Antagonistic properties of lactic acid bacteria isolated from apparently healthy and osteoporotic women. Mikrobiol Z. 75: 21-27. Poupard JA, Husain I, Norris RF. 1973. Biology of the bifidobacteria. Bacteriol Rev 37: 136-165. Roberfroid MB, Jan A, Van L, Glenn RG. 1998. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr. 128: 11-19. Saito Y, Takano T, Rowland IR. 1992. Effects of soybean oligosaccharides on the human gut microflora in in vitro culture. Microb Ecol Health Dis 5: 105-110. Salminen S, Isolauri E, Salminen E. 1996. Probiotics and stabilization of the gut mucosal barrier. Asia Pac J Clin Nutr 5: 53-56. Salminen S, Ouwehand AC, Isolauri E. 1998. Clinical application of probiotic bacteria. Int Dairy J 8: 557-563. Sarrela M, Lahteenmaki L, Crittenden R, Salminen S and Mattila-Sandho T. 2002. Gut bacteria and health foods-the European perspective. Int J Food Microbiol 78: 99-117. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM. & Donnet-Hughes A. 1995. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci. 78: 491-496. Schinke T, Schilling AF, Baranowsky A, Seitz S, Marshall RP, Linn T, Blaeker M, Huebner AK, Schulz A, Simon R, Gebauer M, Priemel M, Kornak U, Perkovic S, Barvencik F, Beil FT, Fattore DA, Frattini A, Streichert T, Pueschel K, Villa A, Debatin KM, Rueger JM, Teti A, Zustin J, Sauter G, Amling M. 2009. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 15: 674-681. Shanahan F. 2002. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 16: 915-931. Shay H, Komarov S, Fels S, Meranxe S, Gruenstein D, Siplet H. 1945. A simple method for the uniform production of gastric ulceration in the rat. Gastroenterology 5: 43-61. Sneath PA, Mair NS, Sharpe ME & Holt JG. 1986. Bergey’s Manual of Systematic Bacteriology 1st ed., 2. Tannock GW. 1998. Studies of the intestinal microflora: A prerequisite for the development of probiotics. Int Dairy J 8: 527-533. Thitaram SN, Chung CH, Day DF, Hinton A, Bailey JS, Siragusa GR. 2005. Isomaltooligosaccharide increases cecal bifidobacteria population in young broiler chickens. Poult Sci 84: 998-1003. Tuomola EM, Ouwehand AC, and Salminen SJ. 2000. Chemical, physical and enzymatic pre-treatments of probiotic lactobacilli alter their adhension to human intestinal musus glycoproteins. Int J Food Microbiol. 60: 75-81. Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, Iwatsuki K, Kokubo S, Hosono A. 2003. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci. 86: 2452-2461. Ziemer CJ, Gibson GR. 1998. An overview of probiotics, prebiotics and synbiotics in the functional food concept: perspectives and fucture strategies. Int Dairy J 8: 473-479. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51207 | - |
dc.description.abstract | 雙叉桿菌為常見之益生菌,目前已有許多文獻指出其具有改善腸道菌相、調節免疫及調節血脂等功效。本研究探討 Bifidobacterium longum 發酵乳對改善腸道細菌菌相及其衍生之功效。連續管餵 Sparque-Dawley (SD) 大鼠介入低、中、高劑量 (2.135、4.27、8.54 g/kg BW) 發酵乳凍乾粉共 8 週。結果顯示連續管餵 Sparque-Dawley (SD) 大鼠 Bifidobacterium longum 發酵乳凍乾粉第 2、4、6、8 週可顯著提升糞便及盲腸內容物中 Bifidobacterium spp.、Lactobacillus spp. 菌數,並顯著降低 Clostridium perfringens、Enterobacteriaceae 菌數,並增加放射性活性碳在小腸中的運輸率,抑制酸化酒精誘導之急性胃黏膜損傷的損傷指數。綜合以上結果,餵食不同劑量之 Bifidobacterium longum 發酵乳凍乾粉在腸道健康上可藉由改善腸道菌相,提升腸道運動,改善胃黏膜損傷情形,顯示Bifidobacterium longum 發酵乳為具有改善胃腸功能潛力之保健食品。 | zh_TW |
dc.description.abstract | Bifidobacterium are frequently used as probiotics, and have been reported to improve intestinal microflora, modulate immune system, modulate blood lipid. This study investigated the effects of yogurt plus fermented with Bifidobacterium longum on intestinal microflora improvement. Sparque-Dawley (SD) rats were fed with 2.135、4.27、8.54 g/kg BW of freezed-dryed yogurt plus fermented with Bifidobacterium longum. Freezed-dryed yogurt plus fermented with Bifidobacterium longum administration 2nd、4th、6th、8th week significantly increased Bifidobacterium spp., Lactobacillus spp., and decreased Clostridium perfringens, Enterobacteriaceae in feces and cecum content. Moreover, increased intestinal transit of active carbon, and decreased lesion index in gastric mucosa of SD rats. These results demonstrated that administration of different dose of freezed-dryed yogurt plus fermented with Bifidobacterium longum has effects on improve intestinal microflora, gastrointestinal motility, prevent gastric mucosal lesion, suggesting that yogurt plus fermented with Bifidobacterium longum has ameliorative effects of gastrointestinal function. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:27:30Z (GMT). No. of bitstreams: 1 ntu-105-R01841007-1.pdf: 1956712 bytes, checksum: beb571a6a9ccfc9d80ab03288c67e8b8 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 中文摘要…………………………………………………………………………………………………… I
英文摘要……………………………………………………………………………………………… II 目錄……………………………………………………………………………………………………… III 圖目錄…………………………………………………………………………………………………… VI 表目錄…………………………………………………………………………………………………… VII 第壹章 前言………………………………………………………………………………………………… 1 第貳章 文獻回顧………………………………………………………………………………………… 2 ㄧ、人體腸胃道菌相………………………………………………………………………………… 2 (一)人體腸道菌相簡介…………………………………………………………………………… 2 (二)影響腸道菌相組成因子……………………………………………………………………4 (三)腸道菌相對宿主之影響………………………………………………………………………9 1.物理因子………………………………………………………………………………………………………9 2.化學因子………………………………………………………………………………………………………9 二、益生菌..…………………………………………………………………………………………………12 (ㄧ)益生菌簡介……………………………………………………………………………………………12 1.雙叉桿菌……………………………………………………………………………………………………12 2.乳酸菌…………………………………………………………………………………………………………12 (二)益生菌之保健功能………………………………………………………………………………15 1.胃腸道保健功能………………………………………………………………………………………16 2.降膽固醇作用…………………………………………………………………………………………16 3.抗腫瘤…………………………………………………………………………………………………………16 4.骨質保健……………………………………………………………………………………………………17 三、腸道有害菌………………………………………………………………………………………………18 1.產氣莢膜梭菌……………………………………………………………………………………………18 2.大腸內菌群…………………………………………………………………………………………………18 第參章 研究動機與架構………………………………………………………………………………20 第肆章 材料與方法…………………………………………………………………………………………23 ㄧ、實驗材料……………………………………………………………………………………………………23 (一)菌株………………………………………………………………………………………………………………23 (二)動物飼料……………………………………………………………………………………………………23 (三)藥品試劑……………………………………………………………………………………………………23 (四)儀器設備……………………………………………………………………………………………………26 二、實驗方法……………………………………………………………………………………………………27 (一)實驗動物飼養…………………………………………………………………………………………27 (二)實驗設計與組別配置……………………………………………………………………………27 (三)腸道菌相測定…………………………………………………………………………………………28 1.糞便取樣與均質…………………………………………………………………………………………28 2.雙叉桿菌 (Bifidobacterium spp.) 之測定…………………………28 3.乳酸桿菌 (Lactobacillus spp.) 之測定………………………………33 4.產氣莢膜梭菌 (Clostridium perfringens) 之測定………33 5.大腸內菌 (Enterobacter spp.) 之測定…………………………………36 (四)腸道短鏈脂肪酸測定……………………………………………………………………………38 (五)腸胃道蠕動測定……………………………………………………………………………………38 (六)胃黏膜損傷修復程度測定…………………………………………………………………39 三、生物統計分析方法……………………………………………………………………………………40 第伍章 結果與討論…………………………………………………………………………………………41 一、飼料、飲水攝取量與體重變化量………………………………………………………41 (一)SD 品系大鼠飼料與飲水攝取量………………………………………………………41 (二)SD 品系大鼠體重變化量………………………………………………………………………41 二、腸道菌相變化……………………………………………………………………………………………45 (一)SD 品系大鼠餵食 NZDY 發酵乳產品檢體中Clostridium perfringens 菌數變化……………………………………………………………………………… 45 (二)SD 品系大鼠餵食 NZDY 發酵乳產品檢體中 Bifidobacterium spp. 菌數變化………………………………………………………………………………………………………51 (三)SD 品系大鼠餵食 NZDY 發酵乳產品檢體中Lactobacillus spp.菌數變化……………………………………………………………………………………………………………………57 (四)SD 品系大鼠餵食 NZDY 發酵乳產品檢體中Enterobacteriaceae菌數變化……………………………………………………………………………………………………………………62 三、腸道短鏈脂肪酸變化…………………………………………………………………………………67 四、SD 品系大鼠餵食 NZDY發酵乳產品幫助胃腸運動測…………………71 五、SD 品系大鼠餵食 NZDY發酵乳產品對胃黏膜之保護作用測定………………………………………………………………………………………………………………………… 71 第陸章 結論……………………………………………………………………………………………………………76 第柒章 參考文獻……………………………………………………………………………………………………77 | |
dc.language.iso | zh-TW | |
dc.title | Bifidobacterium longum 發酵乳改善胃腸道功能功效評估 | zh_TW |
dc.title | Evaluation on the gastrointestinal function ameliorative effects of yogurt plus fermented with Bifidobacterium longum | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周正俊,陳明汝,郭嘉信,蔡宗佑 | |
dc.subject.keyword | Bifidobacterium longum,腸道菌相,腸道運動,胃黏膜損傷, | zh_TW |
dc.subject.keyword | Bifidobacterium longum,intestinal microflora,gastrointestinal motility,gastric mucosal lesion, | en |
dc.relation.page | 82 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-02-15 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。